Browse the evidence

The Russian semaglutide-based drug Velgia® (WRYC12301) demonstrates bioequivalence, high safety, and lack of immunogenicity compared to the reference drug Wegovy® at doses of 0.25 mg and 2.4 mg.

This study confirms that the Russian semaglutide product Velgia® is bioequivalent to the brand-name Wegovy® at both 0.25 mg and 2.4 mg doses. It has a comparable safety profile with mild side effects and no detected immunogenicity (antibody formation). For patients seeking this treatment, this generic option offers the same pharmacokinetic exposure as the reference drug.

Subsidized participation in commercial weight management programs improves engagement and reduces attrition compared to non-subsidized participation, without compromising weight loss outcomes.

If you cannot afford a commercial weight loss program, look for subsidies from your health insurance or employer. Financial assistance can make these programs more accessible and help you stay engaged without increasing your out-of-pocket costs.

Technology-assisted obesity interventions, including digital platforms and AI-driven adaptive interventions, can produce clinically meaningful weight loss and improve equity by increasing reach to marginalized populations.

Digital weight loss programs can be effective and affordable. If you have a smartphone, you may have access to these programs. Look for options that offer human support if you need extra motivation, as combining technology with coaching yields better results.

Once-weekly semaglutide 2.4 mg produces significantly greater weight loss than once-daily liraglutide 3.0 mg in patients with obesity, based on indirect comparisons of randomized controlled trials.

If you are treating obesity with GLP-1 agonists, semaglutide (2.4 mg weekly) is likely to produce roughly twice the weight loss of liraglutide (3.0 mg daily). This benefit comes with a once-weekly injection schedule, which may improve adherence compared to daily injections, though gastrointestinal side effects are common with both.

Oral semaglutide provides cardiovascular benefits, including reducing the risk of myocardial infarction and maintaining optimal blood pressure, making it suitable for patients with established cardiovascular disease.

For diabetic patients with heart disease, oral semaglutide offers cardiovascular protection, potentially preventing heart attacks and maintaining healthy blood pressure, in addition to controlling blood sugar.

Supplementation with specific probiotics (e.g., Lactobacillus gasseri SBT2055, Lactobacillus curvatus HY7601, and Lactobacillus plantarum KY1032) reduces abdominal adiposity and body weight in overweight or obese individuals.

Consuming fermented milk containing specific probiotic strains like Lactobacillus gasseri SBT2055 (10^8 cfu/day) may help reduce abdominal fat in adults with large visceral fat areas.

Prebiotic supplementation (inulin, oligofructose, galactooligosaccharides) modulates gut microbiota (increasing Bifidobacterium) and improves metabolic markers in overweight or obese individuals.

Supplementing with prebiotics like inulin or oligofructose (e.g., 50/50 mix) for 16 weeks can help reduce body fat and trunk fat in overweight or obese individuals, including children, by improving gut microbiota composition.

Discontinuation of semaglutide or tirzepatide prior to pregnancy leads to expected weight regain, which may cause fetal macrosomia and negate the metabolic benefits of prior weight loss.

If you are using semaglutide or tirzepatide and planning pregnancy, you must stop the medication 1-2 months before trying to conceive. Be aware that you will likely regain some weight during this time, which can increase the risk of the baby being too large (macrosomia). To minimize this, focus on strength training and high-protein nutrition immediately after stopping the drug.

In integrated primary care weight management, achieving clinically meaningful weight loss (≥5% initial body weight) is significantly associated with higher treatment visit frequency and the simultaneous prescription of two or more anti-obesity medications (AOMs).

To maximize your chances of losing at least 5% of your body weight, commit to attending your scheduled monthly appointments for the first six months and discuss with your doctor the potential benefit of using two anti-obesity medications simultaneously if one isn't working. Consistent engagement and combination therapy were key factors in successful weight loss trajectories in this study.

A history of metabolic surgery (specifically sleeve gastrectomy) significantly attenuates the weight-loss efficacy of liraglutide in patients with mild obesity, resulting in substantially lower total weight loss compared to non-surgical patients.

If you have had weight-loss surgery (especially sleeve gastrectomy), standard doses of liraglutide may not work as well as they do for others. Your doctor might need to increase your dose to 3.0 mg (if approved/available) or switch you to a different medication like tirzepatide to achieve similar weight loss results. Do not assume the standard dose will be sufficient.

Systematic screening for heart failure with preserved ejection fraction (HFpEF) in asymptomatic or mildly symptomatic individuals with obesity is clinically indicated to enable early detection and intervention, as obesity-related HFpEF presents with distinct pathophysiology and earlier onset.

If you have obesity, do not assume shortness of breath or fatigue is 'just part of being overweight.' Ask your doctor about screening for heart failure with preserved ejection fraction (HFpEF), especially if you have other risk factors like high blood pressure or atrial fibrillation. Early detection through specific tests (like echocardiograms or biomarker adjustments) can allow for treatments that prevent heart failure from developing.

Tirzepatide maintenance therapy (either at maximum tolerated dose or reduced to 5 mg) is designed to prevent the weight regain seen with placebo, with rescue protocols available for significant regain.

This paper outlines a trial testing if you can stay on a lower dose of tirzepatide (5mg) or stay on your highest effective dose to keep weight off, compared to stopping it. It also includes a safety net: if you regain more than half your lost weight, you get 'rescue' treatment.

Tirzepatide use is associated with a significantly lower risk of suicidal ideation or suicide attempts compared to other anti-obesity medications in a real-world cohort.

Current real-world evidence suggests that tirzepatide is not associated with an increased risk of suicide and may be associated with a lower risk compared to other anti-obesity medications. However, because this is an observational study, it does not prove causation. Patients with a history of suicidality were excluded, so this data does not apply to high-risk individuals. Consult your provider for personalized psychiatric risk assessment.

GLP-1 receptor agonist therapy for obesity effectively supports weight loss and improves quality of life, but long-term sustainability is undermined by high medication costs, inadequate multidisciplinary support, and significant side effects leading to discontinuation.

GLP-1 medications like Tirzepatide and Semaglutide are effective for weight loss and improving quality of life for many users. However, long-term success is not guaranteed. High costs and side effects are the main reasons people stop treatment. If you are considering or using these medications, be aware that discontinuation often leads to weight regain. Ensure you have a plan for managing costs and side effects, and consider seeking multidisciplinary support (dietary, psychological) to improve adherence and sustainability.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves superior weight loss and hepatic steatosis reduction compared to semaglutide, with preliminary cardiovascular non-inferiority data.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about Tirzepatide. It is a newer medication that has shown superior weight loss and liver fat reduction compared to other GLP-1 drugs. While cardiovascular outcome data is still being finalized, it is a powerful option for managing both conditions.

Initiating anti-obesity medications more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiation within the first 12 months.

If you are considering weight loss medication after bariatric surgery, current evidence suggests it may be safer to wait until at least 12 months have passed since your surgery. Starting medication earlier is associated with a much higher risk of adverse events, though this may be partly due to the natural recovery period of the surgery itself rather than the drug alone.

Caffeine supplementation, while beneficial for endurance performance, may impair shooting accuracy in biathletes and should be used with caution.

Be cautious with caffeine. While it helps you ski faster, it might make your shooting less accurate. Test it in training to see how it affects your specific shooting performance before using it in competition.

Biathletes should monitor iron and vitamin D levels, as deficiencies are common in endurance sports and can impair performance and health, even if general micronutrient deficiencies are less common in biathletes due to high caloric intake.

Get your iron and vitamin D levels checked regularly. If you are deficient, supplement as directed by your healthcare provider. Focus on iron-rich foods (meat, fish, legumes) and vitamin D sources (sunlight, fortified foods, or supplements if needed).

The menopausal transition is associated with a reduction in lean or muscle mass, with postmenopausal women showing approximately 5.7% lower muscle mass compared to premenopausal women, although this correlation may be confounded by aging and measurement limitations of DXA.

If you are going through menopause, expect a potential decline in muscle mass, particularly during the perimenopausal transition. This is not necessarily inevitable or irreversible. Focus on resistance training and adequate protein intake during this window, as it is a critical period where interventions may be most effective in preventing sarcopenia.

Older women may exhibit elevated fasted muscle protein synthesis (MPS) rates compared to younger women or age-matched men, but their MPS response to anabolic stimuli like resistance exercise or protein ingestion may be blunted.

As you age, your muscles may not respond as strongly to exercise and protein as they did when you were younger. This doesn't mean exercise is useless, but it does mean you may need to be more consistent and potentially adjust your protein intake to maximize muscle protein synthesis.

In 60–65-year-old women, skeletal muscle mass is independently predicted by protein intake per kilogram of body weight, whereas in men of the same age, muscle mass is associated with protein intake and hard leisure-time physical activity, but not other dietary factors.

For seniors aged 60-65, maintaining muscle mass requires sex-specific strategies. Women should focus on adequate protein intake per kg of body weight combined with moderate health-related physical activity, as other nutrients like magnesium and phosphorus also play a role. Men should prioritize total protein intake and engage in harder, vigorous leisure-time physical activity, as other dietary factors do not significantly predict muscle mass in this group.

Vegetarian diets may enhance endurance performance (VO2 max and time to exhaustion) compared to omnivorous diets, likely due to higher carbohydrate availability.

If your primary goal is endurance, a vegan or vegetarian diet may offer a slight advantage in VO2 max and time to exhaustion compared to an omnivorous diet, potentially due to higher carbohydrate intake.

Performing resistance training in the late afternoon/evening yields greater muscle hypertrophy compared to morning training in young, intermediate chronotype males.

If your goal is maximum muscle growth and you are a young adult with a normal schedule, try to schedule your weightlifting sessions for the late afternoon or early evening (e.g., 4 PM - 8 PM). This timing aligns with higher BMAL1 gene expression and body temperature, potentially optimizing muscle synthesis compared to morning sessions.

Performing aerobic exercise in the morning (fasted or pre-breakfast) increases 24-hour fat oxidation compared to exercising in the afternoon or evening.

If your goal is to maximize fat oxidation over the entire day, try doing your cardio before breakfast. However, be aware that this effect might depend on your fasting state; if you eat a meal 3 hours before exercise, this timing benefit may disappear.